Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Income from Continuing Operations data on file, last reported at 4970000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 63.4% year-over-year to 4970000.0 in Q1 2026; TTM through Mar 2026 was 82128000.0, a 240.79% increase from a year earlier, with the FY2025 full-year figure at 73519000.0, up 230.31% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 4970000.0, down from 28648000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for TBPH reached as high as 54835000.0 in Q2 2025 and fell as low as 40259000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 7804647.06 across 5 years, with a median of 13579000.0 in 2025.
• Across the five-year window, Income from Continuing Operations sank 192.8% in 2024 and jumped 431.75% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 14256000.0 in 2022, then surged by 62.8% to 5303000.0 in 2023, then tumbled by 192.8% to 15527000.0 in 2024, then soared by 284.5% to 28648000.0 in 2025, then sank by 117.35% to 4970000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 4970000.0 in Q1 2026, 28648000.0 in Q4 2025, and 3615000.0 in Q3 2025.